Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Levo USA
Chicago, Illinois, USA
- Ownership
- Private
- Development stage
- Other
01
Overview
Levo Therapeutics was a clinical-stage biopharmaceutical company dedicated to developing novel therapies for Prader-Willi Syndrome (PWS) and other complex orphan diseases. The company's lead candidate, LV-101 (intranasal carbetocin), was an oxytocin analog designed to address the behavioral and endocrine symptoms of PWS, specifically hyperphagia and anxiety. Following a Phase 3 clinical trial (CARE-PWS), the company sought regulatory approval but faced challenges with the FDA's assessment of the data. In June 2022, Levo Therapeutics was acquired by Ipsen to integrate LV-101 into Ipsen's rare disease portfolio and continue its development path.
- Therapeutic areas
- Rare Diseases
- Modalities
- PeptidesSmall molecule
- Industry
- Biotech
Beyond the preview
Go deeper on Levo USA.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Levo USA.